Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark Therapeutics, Alkeus Pharmaceuticals, Novartis Pharmaceuticals, Beacon Thera...
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: PR Newswire
DelveInsight's analysts estimate that the inherited retinal diseases market is poised to show significant growth, mainly attributed to increasing prevalence, drug approvals, and anticipated launch of novel therapies during the forecast period (2023–2034).LAS VEGAS, May 22, 2024 /PRNewswire/ -- DelveInsight's Inherited Retinal Disease Market Insights report includes a comprehensive understanding of current treatment practices, inherited retinal disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].Key Takeaways from the Inherited Retinal Disease Market ReportAccording to DelveInsight's analysis, the market size for inherited retinal disease is expected to grow significantly by 2034.As per DelveInsight's estimates, the prevalent population of retinitis pigmentosa and choroideremia in the US was found to be
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
- Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in JapanGlobeNewswire
- Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark Therapeutics, Alkeus Pharmaceuticals, Novartis Pharmaceuticals, Beacon Therapeutics, GenSight Biologics, Ocugen, AbbViePR Newswire
- Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $57.00 price target on the stock.MarketBeat
- Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
BLTE
Earnings
- 5/13/24 - Beat
BLTE
Sec Filings
- 6/4/24 - Form 144
- 5/30/24 - Form 144
- 5/30/24 - Form 144
- BLTE's page on the SEC website